Literature DB >> 21834760

Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection.

Richard van Altena1, Sridevi Duggirala, Matthias I P Gröschel, Tjip S van der Werf.   

Abstract

Humans have always lived with tubercle bacilli. Host susceptibility both inherited and acquired determines whether an individual infected with Mycobacterium tuberculosis will eventually fall ill and develop tuberculosis (TB). After infection with M. tuberculosis, a latent TB infection may ensue reflected by immune recognition of specific antigenic epitopes expressed by M. tuberculosis the Region of Difference 1 proteins ESAT-6 and CFP-10 leading to interferon gamma release in vitro. Multi-Drug-Resistant TB has emerged as an enormous infectious threat in certain regions in the world, and the Acquired immunodeficiency by co-infection with HIV has accelerated the TB epidemic even further. A paradoxical response or Immune Response Inflammatory Syndrome in the context of treatment of HIV co-infection - is an increased inflammatory reaction during effective reduction in the bacterial load. This should be differentiated from treatment failure. A huge challenge is to develop novel markers that can differentiate paradoxical responses from treatment failure. We discuss the role of protection of vaccines especially BCG, iron metabolism and the role of vitamin D.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21834760     DOI: 10.2174/138161211797470228

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  7 in total

Review 1.  Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

Authors:  Satria A Prabowo; Matthias I Gröschel; Ed D L Schmidt; Alena Skrahina; Traian Mihaescu; Serap Hastürk; Rotislav Mitrofanov; Edita Pimkina; Ildikó Visontai; Bouke de Jong; John L Stanford; Père-Joan Cardona; Stefan H E Kaufmann; Tjip S van der Werf
Journal:  Med Microbiol Immunol       Date:  2012-11-10       Impact factor: 3.402

2.  Serum levels of neopterin during antimicrobial treatment for Mycobacterium ulcerans infection.

Authors:  Janine de Zeeuw; Sridevi Duggirala; Willemien A Nienhuis; K Mohammed Abass; Wilson Tuah; Till F Omansen; Tjip S van der Werf; Ymkje Stienstra
Journal:  Am J Trop Med Hyg       Date:  2013-07-08       Impact factor: 2.345

3.  The TB-specific CD4(+) T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans.

Authors:  Bianca R Mothé; Cecilia S Lindestam Arlehamn; Courtney Dow; Myles B C Dillon; Roger W Wiseman; Patrick Bohn; Julie Karl; Nadia A Golden; Trey Gilpin; Taylor W Foreman; Mark A Rodgers; Smriti Mehra; Thomas J Scriba; JoAnne L Flynn; Deepak Kaushal; David H O'Connor; Alessandro Sette
Journal:  Tuberculosis (Edinb)       Date:  2015-08-28       Impact factor: 3.131

4.  The discovery and identification of a candidate proteomic biomarker of active tuberculosis.

Authors:  Jiyan Liu; Tingting Jiang; Liliang Wei; Xiuyun Yang; Chong Wang; Xing Zhang; Dandan Xu; Zhongliang Chen; Fuquan Yang; Ji-Cheng Li
Journal:  BMC Infect Dis       Date:  2013-10-29       Impact factor: 3.090

Review 5.  PET/CT imaging of Mycobacterium tuberculosis infection.

Authors:  Alfred O Ankrah; Tjip S van der Werf; Erik F J de Vries; Rudi A J O Dierckx; Mike M Sathekge; Andor W J M Glaudemans
Journal:  Clin Transl Imaging       Date:  2016-03-07

6.  Corticosteroid therapy for the management of paradoxical inflammatory reaction in patients with pulmonary tuberculosis.

Authors:  Macky M Done; Onno W Akkerman; Wud Al-Kailany; Wiel C M de Lange; Gonda de Jonge; Johanneke Kleinnijenhuis; Riejanne Stienstra; Tjip S van der Werf
Journal:  Infection       Date:  2020-04-24       Impact factor: 3.553

7.  Proteomic profiling for plasma biomarkers of tuberculosis progression.

Authors:  Qiuyue Liu; Liping Pan; Fen Han; Baojian Luo; Hongyan Jia; Aiying Xing; Qi Li; Zongde Zhang
Journal:  Mol Med Rep       Date:  2018-06-05       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.